Horizon: Phase 2 Sjögren’s Syndrome Candidate Meets Primary Endpoint

 Trial also met primary endpoint in first study population as announced September 2022 –

- The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations -

https://finance.yahoo.com/news/horizon-therapeutics-plc-announces-phase-130000899.html